|
Volumn 32, Issue SUPPL. 72, 2005, Pages 36-38
|
Is early intervention worth it?
|
Author keywords
Biologic therapy; Cost benefit analysis; Rheumatoid arthritis
|
Indexed keywords
BIOLOGICAL PRODUCT;
CYCLOOXYGENASE 2 INHIBITOR;
ETANERCEPT;
INFLIXIMAB;
CONFERENCE PAPER;
COST BENEFIT ANALYSIS;
COST EFFECTIVENESS ANALYSIS;
COST OF ILLNESS;
DRUG COST;
EMPLOYMENT;
HEALTH INSURANCE;
HOSPITAL CHARGE;
HUMAN;
JOINT PROSTHESIS;
MEDICAL ETHICS;
ORTHOPEDIC SURGERY;
PRIORITY JOURNAL;
QUALITY ADJUSTED LIFE YEAR;
RHEUMATOID ARTHRITIS;
TAX;
WORK;
WORKMAN COMPENSATION;
CANADA;
ECONOMICS;
REVIEW;
RHEUMATOLOGY;
UNITED STATES;
ARTHRITIS, RHEUMATOID;
CANADA;
COST OF ILLNESS;
COST-BENEFIT ANALYSIS;
HUMANS;
RHEUMATOLOGY;
UNITED STATES;
|
EID: 17144383980
PISSN: 0315162X
EISSN: None
Source Type: Journal
DOI: None Document Type: Conference Paper |
Times cited : (9)
|
References (9)
|